1-7 of 7
Christoph Uherek
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, MD, Asher Chanan-Khan, MD, Leonard T. Heffner, MD, David Avigan, MD, Todd M. Zimmerman, MD, Sagar Lonial, MD, Robert J. Lutz, PhD, Andre Engling, PhD, Christoph Uherek, PhD, Frank Osterroth, PhD, Markus Ruehle, MD, Michelle A. Beelitz, Gabriele Niemann, PhD, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD
Journal: Blood
Blood (2011) 118 (21): 305.
https://doi.org/10.1182/blood.V118.21.305.305
Published: 2011
Journal Articles

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, MD, Asher A. Chanan-Khan, MD, Leonard T Heffner, MD, David Avigan, MD, Robert J Lutz, PhD, Christoph Uherek, PhD, Frank Osterroth, PhD, Markus Ruehle, MD, Thomas Haeder, PhD, Gabriele Niemann, PhD, Andrea Wartenberg-Demand, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson
Journal: Blood
Blood (2010) 116 (21): 3060.
https://doi.org/10.1182/blood.V116.21.3060.3060
Published: 2010
Journal Articles

BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib

Chantal Zuber, PhD, Benjamin Daelken, PhD, Silke Aigner, PhD, Thomas Haeder, PhD, Olga Ab, PhD, Kathleen Whiteman, PhD, Teru Hideshima, Robert J Lutz, PhD, Frank Osterroth, PhD, Christoph Uherek, PhD
Journal: Blood
Blood (2010) 116 (21): 3008.
https://doi.org/10.1182/blood.V116.21.3008.3008
Published: 2010
Journal Articles

Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.

Asher A. Chanan-Khan, MD, Sundar Jagannath, MD, Leonard T. Heffner, David Avigan, MD, Kelvin P. Lee, MD, Robert J Lutz, PhD, Thomas Haeder, PhD, Markus Ruehle, MD, Christoph Uherek, PhD, Andrea Barbara Wartenberg-Demand, MD, Nikhil Munshi, Kenneth C. Anderson, MD
Journal: Blood
Blood (2009) 114 (22): 1862.
https://doi.org/10.1182/blood.V114.22.1862.1862
Published: 2009
Journal Articles

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.

Hiroshi Ikeda, MD, PhD, Teru Hideshima, MD, PhD, Robert J. Lutz, Sonia Vallet, Samantha Pozzi, MD, Loredana Santo, Elisabetta Calabrese, Benjamin Dälken, Christoph Uherek, Silke Aigner, Frank Osterroth, Mariateresa Fultiniti, Yutaka Okawa, Giulia Perrone, Gullu Gorgun, Hiroshi Yasui, Diana Cristia, Noopur Raje, MD, Nikhil Munshi, MD, Paul Richardson, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2008) 112 (11): 1716.
https://doi.org/10.1182/blood.V112.11.1716.1716
Published: 2008
Journal Articles

Re-Targeting of an NK Cell Line (NK92) with Specificity for CD19 Efficiently Kills Human B-Precursor Leukemia Cells.

Annette Romanski, Christoph Uherek, Gesine Bug, Tina Muller, Claudia Rossig, Manuela Kampfmann, Nicola Krossok, Dieter Hoelzer, Erhard Seifried, Winfried Wels, Oliver G. Ottmann, Torsten Tonn
Journal: Blood
Blood (2004) 104 (11): 2747.
https://doi.org/10.1182/blood.V104.11.2747.2747
Published: 2004
Journal Articles

Retargeting of natural killer–cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction

Christoph Uherek, Torsten Tonn, Barbara Uherek, Sven Becker, Barbara Schnierle, Hans-Georg Klingemann, Winfried Wels
Journal: Blood
Blood (2002) 100 (4): 1265–1273.
https://doi.org/10.1182/blood.V100.4.1265.h81602001265_1265_1273
Published: 2002